Open an account

Cytokinetics

CYTK · NASDAQ

$63.95+$1.30 (+2.08%)TodayMarket closed ·
Prev close $62.65

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The company is headquartered in South San Francisco, California and currently employs 673 full-time employees. The company went IPO on 2004-04-29. The firm is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The firm is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

Employees
673
Headquarters
South San Francisco, California
Listed
Apr 29, 2004
Sector
Health Care
Industry
Biotechnology
Website
cytokinetics.com

CYTK key statistics

Market cap
8.71B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.09M
Volume
1.05M
Open price
$63.13
High today
$64.76
Low today
$62.88
52 Week high
$88.31
52 Week low
$54.30

Cytokinetics (CYTK) at a glance

Cytokinetics (CYTK) last traded at $63.95, with a market cap of 8.71B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $62.88 and $64.76. The current price is 1.7% above the day's low and 1.2% below its high.

Volume so far is 1.05M shares, below the average of 2.09M shares a day.

Over the past year Cytokinetics has ranged from $54.30 to $88.31, and now sits 28% of the way up that range.

Cytokinetics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.50 per share against an estimate of -$1.67.

The average analyst price target is $112.47, 75.9% above the current price, from 19 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 19 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 22 analystsAvg $112.47
Low
$85.85
Now
$63.95
High
$153.30

CYTK earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 8.2% on average.

  1. Q3 FY24: reported -$1.36 per share against an estimate of -$1.27
  2. Q4 FY24: reported -$1.26 per share against an estimate of -$1.22
  3. Q1 FY25: reported -$1.39 per share against an estimate of -$1.41
  4. Q2 FY25: reported -$1.12 per share against an estimate of -$1.40
  5. Q3 FY25: reported -$2.55 per share against an estimate of -$1.61
  6. Q4 FY25: reported -$1.50 per share against an estimate of -$1.49
  7. Q1 FY26: reported -$1.67 per share against an estimate of -$1.69
  8. Q2 FY26: reported -$1.50 per share against an estimate of -$1.67

CYTK news

  • Chandrima Sanyal

    Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

  • Vandana Singh

    Cytokinetics Investors Weigh Safety Data From Pivotal Trial

  • Chandrima Sanyal

    New AI ETF Bets on Healthcare's $9 Trillion Opportunity

  • Vandana Singh

    Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • 10 Health Care Stocks With Whale Alerts In Today's Session

  • Preview: Cytokinetics's Earnings

  • Press releaseGlobe Newswire

    Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

Similar companies

Companies in the same industry as Cytokinetics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.